Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

(2011) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

Demyelination versus remyelination in progressive multiple sclerosis

(2010) Stephan Bramow et al.   BRAIN

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

(2010) Mads Ravnborg et al.   LANCET NEUROLOGY

Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

(2010) Roberta Lanzillo et al.   Multiple Sclerosis Journal

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial

(2010) Richard E Gonsette et al.   Multiple Sclerosis Journal

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

(2010) M. P. Sormani et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

(2009) Per Soelberg Sorensen et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis

(2009) E Havrdova et al.   Multiple Sclerosis Journal

Contribution of relapses to disability in multiple sclerosis

(2008) C. Hirst et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE